Dr. Brad Vince of Vince & Associates Clinical Research Announces Award of Nearly $10 Million Contract from the National Institute on Drug Abuse
Vince & Associates Clinical Research
announced it has been awarded a contract with the
National Institute on Drug Abuse
, part of the
National Institutes of Health (NIH)
, to carry out clinical pharmacology studies to determine the pharmacokinetics and pharmacodynamics of new medication in humans.
This award is a five year contract with a ceiling value of $9,695,476 beginning September 2012. Vince and Associates will conduct clinical pharmacology studies to support the development of new medications for the treatment of substance abuse disorders.
“Our organization will research investigational medications to include new chemical entities, new biological products such as monoclonal antibodies, enzymes and vaccines as well as already approved drug products,” said
Dr. Brad Vince
, president and medical director of Vince & Associates Clinical Research. “Our organization is excited to work on clinical studies with NIDA that may benefit those struggling with substance abuse disorders.”
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
